Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NUP85_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NUP85_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NUP85_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NUP85_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051168111 | Skin | cSCC | nuclear export | 91/4864 | 154/18723 | 3.33e-18 | 4.18e-16 | 91 |
GO:0034504110 | Skin | cSCC | protein localization to nucleus | 143/4864 | 290/18723 | 8.98e-18 | 1.02e-15 | 143 |
GO:005065719 | Skin | cSCC | nucleic acid transport | 92/4864 | 163/18723 | 1.35e-16 | 1.33e-14 | 92 |
GO:005065819 | Skin | cSCC | RNA transport | 92/4864 | 163/18723 | 1.35e-16 | 1.33e-14 | 92 |
GO:005123619 | Skin | cSCC | establishment of RNA localization | 93/4864 | 166/18723 | 1.78e-16 | 1.69e-14 | 93 |
GO:005102816 | Skin | cSCC | mRNA transport | 77/4864 | 130/18723 | 1.06e-15 | 8.95e-14 | 77 |
GO:0017038110 | Skin | cSCC | protein import | 100/4864 | 206/18723 | 2.50e-12 | 1.36e-10 | 100 |
GO:007116613 | Skin | cSCC | ribonucleoprotein complex localization | 49/4864 | 77/18723 | 3.94e-12 | 2.13e-10 | 49 |
GO:001593119 | Skin | cSCC | nucleobase-containing compound transport | 105/4864 | 222/18723 | 5.49e-12 | 2.89e-10 | 105 |
GO:007142613 | Skin | cSCC | ribonucleoprotein complex export from nucleus | 48/4864 | 76/18723 | 9.76e-12 | 4.97e-10 | 48 |
GO:005117016 | Skin | cSCC | import into nucleus | 77/4864 | 159/18723 | 9.17e-10 | 3.58e-08 | 77 |
GO:000660615 | Skin | cSCC | protein import into nucleus | 73/4864 | 155/18723 | 1.13e-08 | 3.48e-07 | 73 |
GO:000640513 | Skin | cSCC | RNA export from nucleus | 46/4864 | 84/18723 | 1.89e-08 | 5.56e-07 | 46 |
GO:003150315 | Skin | cSCC | protein-containing complex localization | 95/4864 | 220/18723 | 2.00e-08 | 5.82e-07 | 95 |
GO:000640612 | Skin | cSCC | mRNA export from nucleus | 34/4864 | 59/18723 | 2.59e-07 | 5.33e-06 | 34 |
GO:007142712 | Skin | cSCC | mRNA-containing ribonucleoprotein complex export from nucleus | 34/4864 | 59/18723 | 2.59e-07 | 5.33e-06 | 34 |
GO:009758118 | Skin | cSCC | lamellipodium organization | 42/4864 | 90/18723 | 1.83e-05 | 2.19e-04 | 42 |
GO:003003215 | Skin | cSCC | lamellipodium assembly | 32/4864 | 72/18723 | 5.20e-04 | 3.90e-03 | 32 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa0301321 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa0301331 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
hsa0501422 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
hsa03013 | Liver | HCC | Nucleocytoplasmic transport | 81/4020 | 108/8465 | 4.28e-09 | 6.83e-08 | 3.80e-08 | 81 |
hsa0501432 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
hsa030131 | Liver | HCC | Nucleocytoplasmic transport | 81/4020 | 108/8465 | 4.28e-09 | 6.83e-08 | 3.80e-08 | 81 |
hsa0501428 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
hsa030136 | Oral cavity | OSCC | Nucleocytoplasmic transport | 82/3704 | 108/8465 | 7.93e-12 | 1.33e-10 | 6.77e-11 | 82 |
hsa05014112 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
hsa0301311 | Oral cavity | OSCC | Nucleocytoplasmic transport | 82/3704 | 108/8465 | 7.93e-12 | 1.33e-10 | 6.77e-11 | 82 |
hsa0501429 | Oral cavity | LP | Amyotrophic lateral sclerosis | 197/2418 | 364/8465 | 1.25e-25 | 1.39e-23 | 8.93e-24 | 197 |
hsa030132 | Oral cavity | LP | Nucleocytoplasmic transport | 53/2418 | 108/8465 | 4.68e-06 | 4.10e-05 | 2.64e-05 | 53 |
hsa0501437 | Oral cavity | LP | Amyotrophic lateral sclerosis | 197/2418 | 364/8465 | 1.25e-25 | 1.39e-23 | 8.93e-24 | 197 |
hsa030133 | Oral cavity | LP | Nucleocytoplasmic transport | 53/2418 | 108/8465 | 4.68e-06 | 4.10e-05 | 2.64e-05 | 53 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NUP85 | SNV | Missense_Mutation | novel | c.1616G>T | p.Gly539Val | p.G539V | Q9BW27 | protein_coding | deleterious(0.05) | probably_damaging(0.997) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
NUP85 | SNV | Missense_Mutation | novel | c.224N>T | p.Ser75Phe | p.S75F | Q9BW27 | protein_coding | deleterious(0) | possibly_damaging(0.792) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
NUP85 | SNV | Missense_Mutation | | c.827N>T | p.Thr276Ile | p.T276I | Q9BW27 | protein_coding | deleterious(0) | benign(0.112) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
NUP85 | SNV | Missense_Mutation | novel | c.673N>T | p.Ala225Ser | p.A225S | Q9BW27 | protein_coding | tolerated(0.84) | benign(0.001) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
NUP85 | insertion | Frame_Shift_Ins | novel | c.1748_1749insTTTTAAT | p.Leu584PhefsTer18 | p.L584Ffs*18 | Q9BW27 | protein_coding | | | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
NUP85 | insertion | Nonsense_Mutation | novel | c.1749_1750insCATGACTCTTGTTATGTATTTTGA | p.Pro583_Leu584insHisAspSerCysTyrValPheTer | p.P583_L584insHDSCYVF* | Q9BW27 | protein_coding | | | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
NUP85 | deletion | In_Frame_Del | | c.1692_1694delNNN | p.Thr565del | p.T565del | Q9BW27 | protein_coding | | | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NUP85 | SNV | Missense_Mutation | | c.13N>A | p.Asp5Asn | p.D5N | Q9BW27 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
NUP85 | SNV | Missense_Mutation | | c.320N>T | p.Ser107Leu | p.S107L | Q9BW27 | protein_coding | deleterious(0) | possibly_damaging(0.826) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
NUP85 | SNV | Missense_Mutation | | c.234N>G | p.Ile78Met | p.I78M | Q9BW27 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-Q1-A73R-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |